Advancing HCV Care at Point of Service – using Technology at the Right Place for the Right Patient

This webinar was presented as an industrial symposium in the 23^rd Bangkok International Symposium on HIV Medicine 2021

Moderator

Tan Swee Jin, PhD, PMP

Senior Manager, Scientific Affairs, Sysmex Asia Pacific

Singapore

Speaker

Mark Sonderup, B PharmMBChB FCP (SA) MMED FRCP

Associate Professor and Hepatologist, Department of Medicine and Division of Hepatology at UCT Private Academic Hospital

South Africa

Panelists

Ekta Gupta, MD, MBBS

Professor and Head, Clinical Virology and nodal officer for WHO Collaborative Centre on Viral Hepatitis at the Institute of Liver and Biliary Sciences

India

Tanyaporn Wansom, MD, PhD, MPP

Director of Research and Advocacy at Dreamlopments and protocol chair of the C-Free Study

Thailand

Objectives of the Lecture

Chronic infection with Hepatitis C Virus (HCV) is a major public health problem, affecting 185 million people worldwide. The new highly effective direct acting antivirals (DAAs) provide transformative therapies for chronic HCV infection and are expected to turn the tide of increasing liver-related problems and early death. For this HCV treatment program to have major impact, the bottleneck remains at patient awareness, disease detection and linkage to care. The main challenges impeding disease detection are asymptomatic patients during the acute phase and the lack of access to diagnostic testing.

In this webinar, we draw on the experience of a prominent hepatologist to share how Genedrive changes the practice for confirmation of HCV viremia for treatment of chronic HCV in People Who Inject Drug (PWID) populations in South Africa.

Abstract of Lecture

The 2016 WHO adoption of the global elimination of viral hepatitis strategy has brought into sharp focus the need to innovate around diagnostics. With respect to hepatitis C, given the advances in therapeutics that are simple, well tolerated, short course and all-oral, elimination is now possible. However, to link patients to care, they need to be identified and diagnosed. Furthermore, to achieve elimination, targeting key population groups driving new infection, is vital. The traditional model of care where those with infection are seen within a hospital or clinic environment, with diagnostics being performed by a central laboratory, is not suited to key population needs. The resultant effect is a lost opportunity for care and thus negatively influencing any elimination efforts. Key populations, such as people who inject drugs (PWID), require simple point of service diagnostics that immediately links them to care and similarly, monitored in the same manner. The symposium will explore these issues and highlight a treatment project in South Africa utilizing the Genedrive technology.

* The Genedrive instrument and HCV ID kit are distributed exclusively by Sysmex Asia Pacific in Asia Pacific Region except for India.

Watch Video

We hope you will enjoy the webinar and thereafter spare us a few minutes of your time to fill a short survey.

Scan Here